36.6 F
New York
Wednesday, January 27, 2021

AstraZeneca [NYSE: AZN] Announces $6 Billion Cancer Drug Deal With Daiichi Sankyo

Must read

JPMorgan [NYSE: JPM] Announced To Initiate A Digital Retail Bank In The United Kingdom

JPMorgan Chase revealed that the company will launch a new digital retail bank in the United Kingdom offering the customer of the region...

Humanigen [NASDAQ: HGEN] Announces Expansion Of Manufacturing Agreement With Ajinomoto Bio-Pharma

Humanigen Inc revealed that the company has extended the manufacturing agreement with  Ajinomoto BioPharma to support the fill-finish of Lenzilumab. The Lenzilumab is...

Synchrony [NYSE: SYF] Announced To Purchase Allegro Credit

Synchrony Financials revealed that the company entered into a definitive contract to Purchase Allegro Credit. Allegro Credit's customer base and merchant network will...

Vericel Corp [NASDAQ: VCEL] Names Joe Mara As The New CFO

Vericel Corporation revealed that the company has named Joe Mara as the CFO of the company. He has over more than 20 years...

AstraZeneca PLC announced Monday it has signed a $6 billion deal with Japan’s second-largest pharmaceutical company, Daiichi Sankyo for the making and introduction of new antibody-drug conjugate (ADC).

The new deal inked among two companies for the making of DS-1062, TROP2 directed antibody-drug conjugate (ADC) of Daiichi, and for the new drugs for the treatment of various tumors type. British pharmaceutical company unveiled that the drug is currently in the development stage.

DS-1062 is currently in the making for the treatment of multiple tumors that typically exhibit cell surface glycoprotein TROP2. TROP2 is a transmembrane glycoprotein. It is differently exhibited in many cancers and it is overexpressed in many cancer cells.

TROP2 overexpression leads to the growth and proliferation of cancer cells. It is a promising target for the development process. While DS-1062 is a TROP2 directed ADC.

Shares of AstraZeneca soared 1.14% during the trading of Friday. It has a closing price of $55.80. In the past 52-weeks of trading, its stocks fluctuated between the low of $36.15 and a high of $64.94. AZN has moved up 54.36% from its 52-weeks low and moved down -14.07% from its 52-weeks high.

If we look at its profitability, it has a return on assets of 2.50%, return on investment of 8.30% and return on equity of 12.30%. British giant has a gross margin of 79.60%, a profit margin of 6.00%, and an operating margin of 12.10%. AZN has a market cap of 146.21 billion. If we look at its liquidity, it has a quick ratio of 0.60 and a current ratio of 0.80.

As per the contract, AstraZeneca will pay the upfront payment of $1 billion in staged payment, $350 million is due upon completion, $325 million after 12-months, and a $325 million after 24 months from the effective date of the contract. The British giant will pay $1 billion for the successful regulatory approval and will pay $4 billion for sales-related milestones.

Both the companies will jointly work to make and introduce DS-1062 worldwide except in Japan where Daiichi will maintain exclusive rights. As per the deal, both Daiichi and AstraZeneca will share all the expenses and the profits equally incurred in the development and commercialization of DS-1062.

More articles

Latest article

A Paychex [NASDAQ: PAYX] Subsidiary Announces Strategic Collaboration With Zoho Books

SurePayroll, a subsidiary of Paychex company revealed that the company has formed a collaboration with Zoho books. SurePAyroll is a provider of small...

MGP Ingredients [NASDAQ: MGPI] Announced To Acquire Luxco and Its Affiliate Companies

MGP Ingredients  revealed a definitive contract to purchase Luxco, Inc and its affiliated companies. Luxco is an alcohol beverage company with more than 60...

Conformis [NASDAQ: CFMS] Entered A Non-Exclusive agreement with SITES Medical

Conformis Inc revealed that the company inked a development and supply contract with sites medical. Both of the companies will work together to...

Colliers International [NASDAQ: CIGI] Announces Executive Leadership Changes For Australian Business

Colliers International  reported that the company has named Malcom Tyson as the new Chief Executive Officer. He is appointed as the CEO so...

Korn Ferry [NYSE: KFY] Announces Expansion Of Its Footprint In Russian Market

Korn Fery revealed that the company is expanding its footprint in Russia. Moreover, it is adding a high expertise team of executive search...

Haemonetics [NYSE: HAE] To Purchase Cardiva For An Upfront Payment Of $475M

Haemonetics Corporation revealed that the company has inked a definitive contract to purchase Cardiva Medical Inc. Under the contract, Haemontics will pay an...

Philips [NYSE: PHG] To Purchase Capsule Technologies For Cash Consideration Of USD 635M

Koninklijke Philip revealed that the company has inked a contract to purchase Capsule technologies. The company will pay a cash price of $636...

Thermo Fisher Scientific [NYSE: TMO] To Purchase Mesa Biotech For Approx. $450M In Cash

Thermo fisher scientific inc revealed that the company has signed a definitive contract to purchase Mesa Biotech. Thermo will pay a value price...